Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

Subjects:

Analysis of immune cells in brown trout kidney from the three fish rearing backgrounds (W, W:F, F) with flow cytometry. by Helena Saura Martinez (22305113)

Subjects:

Lens profiles as Ez (orange lines) force was increased and Az and Pz (green lines) forces were decreased. by Ronald A. Schachar (16674576)

LBM-based approach using synchronous transformation with a time step of 0.43s, PNGM-based method using asynchronous transformation with a 5s time step, VGA using explicit scheme wi... by Mouad Klai (20818364)

Subjects:

Comparison of diffusion simulations: implicit scheme of the GDE with a 30-second time step (blue line), implicit scheme of the PNGM with α = 0.6 and a 15-second time step (green li... by Mouad Klai (20818364)

Subjects:

Comparison of diffusion simulation using the implicit and explicit schemes of the graph diffusion equation: the implicit scheme time step was set to 30 seconds, while the explicit... by Mouad Klai (20818364)

Subjects:

The G215S mutation decreases packaging of N and growth in primary differentiated human bronchial cells. by Hannah C. Kubinski (21213168)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

Increase in physical activity (100 step, 500 steps or 1000 steps) after the challenge according to decrease in screen time < or ≥60 minutes. by Annaëlle Le Steunf (19838110)

“…<p>Increase in physical activity (100 step, 500 steps or 1000 steps) after the challenge according to decrease in screen time < or ≥60 minutes.…”

Tissue, days post-infection (dpi) and the top 10 most significant genes with increased and decreased expression with valid gene symbols for the response contrasts. by Gillian P. McHugo (8965919)

Root index data of tomato after two planting stages. by Hongyi Pan (5706971)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects: